- Description
- Details
- Subprojects
- History
- Publications
- Patents
- Trials
| Project Title: | Cancer center support grant | |
| Project Number: | 5P30CA008748-47 | |
| Project web address: | Follow on NIH | |
| Project Description: | ||
|---|---|---|
| Memorial Sloan-Kettering Cancer Center (MSKCC) Memorial Sloan Kettering Cancer Center (MSKCC) is a free-standing institution dedicated to the control of cancer through in-patient and out-patient care, clinical and research training programs, and a broad spectrum of research activities. MSKCC's research programs are grouped into three categories: Basic Research (Regulation of Cell Behavior, Developmental Biology, Genomic Integrity, and Molecular Structure); Bridge Disciplines (Cancer Biology and Experimental Pathology, Experimental Therapeutics, Immunology and Transplantation, and Imaging and Radiation Sciences), and Patient-Oriented Research (Clinical Research and Prevention, Control, and Population Research). The programs are designed to optimize the use of a large patient population and an extensive, multi-disciplinary staff of clinical and laboratory-based investigators and to encourage the application of discoveries in the basic sciences in a way that advances the prevention, detection, diagnosis, and treatment of many forms of cancer. Scientific work in the ten research programs depends on services provided by 34 core facilities, 19 of which will receive funding from the Cancer Center Support Grant (CCSG). During the next five years, MSKCC will continue to enlarge its clinical and research facilities and its research and training programs; therefore, an expanded budget is requested to establish the laboratories of new investigators in several fields of inquiry and to support the core facilities which have grown to support the needs of the research enterprise. | ||
| Project Terms: | ||
| There are no related terms in database. | ||
| Project Title: | Cancer center support grant | |
| Project Number: | 5P30CA008748-47 | |
| Project web address: | Follow on NIH | |
| Organization: | Sloan-Kettering Inst Can Research, United States, New York, NEW YORK | |
| Principal Investigators (PI): |
Thompson Craig B, US
|
|
| Project Categories: | ||
|---|---|---|
|
• Natural Sciences > Aging Diseases and Pathology > Cancer & related diseases > Malignant neoplasms (including in situ) |
||
| Other Information: | ||
| Fiscal Year: | 1997 | |
| Project Start Date: | 20 January 1997 | |
| Project End Date: | 31 December 2014 | Project program: | Center Core Grants |
| Project Funding Information: | ||
| Funding Mechanism: | Research Centers | |
| Year | Funding Organization | Total Funding, $ |
|---|---|---|
| 2012 | NIH - National Cancer Institute | $13,185,550 |
| Project Title: | Cancer center support grant | |
| Project Number: | 5P30CA008748-47 | |
| Project web address: | Follow on NIH | |
| Title | FY | Funding |
|---|---|---|
| Core- glassware washing | 2012 | $470778 |
| Molecular cytology | 2012 | $251118 |
| Research pharmacy | 2012 | $92614 |
| Behavior methods | 2012 | $45175 |
| Microchemistry and proteomics | 2012 | $192201 |
| Molecular cytogenetics | 2012 | $101409 |
| Planning and evaluation | 2012 | $5653316 |
| Monoclonal antibody | 2012 | $158120 |
| Rarc- research animal resource center | 2012 | $1368216 |
| Mouse genetics | 2012 | $482781 |
| Flow cytology | 2012 | $190645 |
| Developmental funds | 2012 | $805050 |
| Pathology | 2012 | $277408 |
| X-ray crystallography | 2012 | $151005 |
| Organ synthesis | 2012 | $180706 |
| Bioinformatics | 2012 | $499158 |
| Gene transfer and somatic cell engineering | 2012 | $206277 |
| Biostatistics | 2012 | $422706 |
| Animal imaging | 2012 | $130823 |
| High-throughput screening | 2012 | $316241 |
| Genomics | 2012 | $372930 |
| Project Title: | Cancer center support grant | |||
| Project Number: | 5P30CA008748-47 | |||
| Project web address: | Follow on NIH | |||
| Title | Journal | Year | Country | Rel |
|---|---|---|---|---|
| Diastereoselective Synthesis of Highly Substituted Tetrahydrofurans by Pd-Catalyzed Tandem Oxidative Cyclization-Redox Relay Reactions Controlled by Intramolecular Hydrogen Bonding. | J Org Chem | 2017 | united states |
|
| Moderators of the effects of meaning-centered group psychotherapy in cancer survivors on personal meaning, psychological well-being, and distress. | Support Care Cancer | 2017 | germany |
|
| Targeting MET in Lung Cancer: Will Expectations Finally Be MET? | J Thorac Oncol | 2017 | united states |
|
| A geometric atlas to predict lung tumor shrinkage for radiotherapy treatment planning. | Phys Med Biol | 2017 | england |
|
| A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer. | Gynecol Oncol | 2017 | united states | |
| Haploinsufficiency of the Transcription Factor Ets-1 Is Renoprotective in Dahl Salt-Sensitive Rats. | J Am Soc Nephrol | 2017 | united states |
|
| Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. | Nat Rev Endocrinol | 2017 | england |
|
| Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. | Cochrane Database Syst Rev | 2017 | england | |
| ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia. | Nature | 2017 | england |
|
| Suppression of lethal autoimmunity by regulatory T cells with a single TCR specificity. | J Exp Med | 2017 | united states |
|
| Gemcitabine kills proliferating endothelial cells exclusively via acid sphingomyelinase activation. | Cell Signal | 2017 | england |
|
| Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases. | Clin Cancer Res | 2017 | united states |
|
| Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. | Cell | 2017 | united states |
|
| Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. | Eur Urol | 2017 | switzerland |
|
| Initial performance studies of a wearable brain positron emission tomography camera based on autonomous thin-film digital Geiger avalanche photodiode arrays. | J Med Imaging (Bellingham) | 2017 | united states |
|
| Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-? inhibitor therapy and literature review. | Ann Diagn Pathol | 2017 | united states |
|
| Patient-Reported Outcomes 1 Year After Immediate Breast Reconstruction: Results of the Mastectomy Reconstruction Outcomes Consortium Study. | J Clin Oncol | 2017 | united states |
|
| Mapping genetic variations to three-dimensional protein structures to enhance variant interpretation: a proposed framework. | Genome Med | 2017 | england |
|
| Pan-Cancer Analysis Links PARK2 to BCL-XL-Dependent Control of Apoptosis. | Neoplasia | 2017 | united states |
|
| Biomarker Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality? | Clin Cancer Res | 2017 | united states | |
| Factors associated with distant recurrence following R0 lobectomy for pN0 lung adenocarcinoma. | J Thorac Cardiovasc Surg | 2017 | united states | |
| Multinuclear NMR and MRI Reveal an Early Metabolic Response to mTOR Inhibition in Sarcoma. | Cancer Res | 2017 | united states |
|
| Effective Prostate-Specific Membrane Antigen-Based 18F-DCFPyL-Guided Cryoablation of a Single Positive Site in a Patient Believed to Be More Metastatic on 11C-Choline PET/CT. | Clin Nucl Med | 2017 | united states |
|
| Women With Breast Cancer Who Work For Accommodating Employers More Likely To Retain Jobs After Treatment. | Health Aff (Millwood) | 2017 | united states |
|
| Structure and reconstitution of yeast Mpp6-nuclear exosome complexes reveals that Mpp6 stimulates RNA decay and recruits the Mtr4 helicase. | Elife | 2017 | england |
|
| Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. | JCO Precis Oncol | 2017 | united states |
|
| Association Between Use of Traditional Chinese Medicine Herbal Therapy and Survival Outcomes in Patients With Stage II and III Colorectal Cancer: A Multicenter Prospective Cohort Study. | J Natl Cancer Inst Monogr | 2017 | united states | |
| Adapting Meaning-Centered Psychotherapy for the palliative care setting: Results of a pilot study. | Palliat Med | 2017 | england |
|
| Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. | Eur Urol | 2017 | switzerland | |
| PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas. | Oncotarget | 2017 | united states |
|
| Contralateral Breast Cancer Risk in Women with Ductal Carcinoma In Situ: Is it High Enough to Justify Bilateral Mastectomy? | Ann Surg Oncol | 2017 | united states |
|
| Benign vascular lesions of the breast diagnosed by core needle biopsy do not require excision. | Histopathology | 2017 | england |
|
| Educating front-line clinicians about antimicrobial resistance. | Lancet Infect Dis | 2017 | united states |
|
| Ontogenetic establishment of order-specific nuclear organization in the mammalian thalamus. | Nat Neurosci | 2017 | united states |
|
| The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype. | Ann Surg Oncol | 2017 | united states |
|
| Quantitating whole lesion tumor biology in rectal cancer MRI: taking a lesson from FDG-PET tumor metrics. | Abdom Radiol (NY) | 2017 | united states | |
| Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer. | Int J Hyperthermia | 2017 | england | |
| Facilitating informed decisions about breast cancer screening: development and evaluation of a web-based decision aid for women in their 40s. | BMC Med Inform Decis Mak | 2017 | england |
|
| Association of Common Genetic Variants With Contralateral Breast Cancer Risk in the WECARE Study. | J Natl Cancer Inst | 2017 | united states | |
| Treatment decisions and employment of breast cancer patients: Results of a population-based survey. | Cancer | 2017 | united states |
|
| The potential of organoids in urological cancer research. | Nat Rev Urol | 2017 | england |
|
| A Practical Framework for Understanding and Reducing Medical Overuse: Conceptualizing Overuse Through the Patient-Clinician Interaction. | J Hosp Med | 2017 | united states |
|
| Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. | Gynecol Oncol | 2017 | united states |
|
| Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. | Cancer Discov | 2017 | united states |
|
| Primitive Neuroectodermal Tumors of the Female Genital Tract: A Morphologic, Immunohistochemical, and Molecular Study of 19 Cases. | Am J Surg Pathol | 2017 | united states |
|
| Surgeon Attitudes and Use of MRI in Patients Newly Diagnosed with Breast Cancer. | Ann Surg Oncol | 2017 | united states | |
| Cost-effectiveness of adjunct non-pharmacological interventions for osteoarthritis of the knee. | PLoS One | 2017 | united states |
|
| Distance in cancer gene expression from stem cells predicts patient survival. | PLoS One | 2017 | united states |
|
| Brain structure and function in patients with ovarian cancer treated with first-line chemotherapy: a pilot study. | Brain Imaging Behav | 2017 | united states |
|
| Chimeric antigen receptor T-cell neuropsychiatric toxicity in acute lymphoblastic leukemia. | Palliat Support Care | 2017 | england |
|
| Implementation of Dynamically Updated Prediction Models at the Point of Care at a Major Cancer Center: Making Nomograms More Like Netflix. | Urology | 2017 | united states |
|
| Isolated pink papule on the chest. | Dermatol Pract Concept | 2017 | united states |
|
| Full Information Maximum Likelihood Estimation for Latent Variable Interactions With Incomplete Indicators. | Multivariate Behav Res | 2017 | united states |
|
| Applications of pHLIP Technology for Cancer Imaging and Therapy. | Trends Biotechnol | 2017 | england |
|
| Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening. | PLoS One | 2017 | united states |
|
| Specimen Identification Errors in Breast Biopsies: Age Matters. Report of Two Near-Miss Events and Review of the Literature. | Breast J | 2017 | united states |
|
| Systemic Therapy for Metastatic Renal-Cell Carcinoma. | N Engl J Med | 2017 | united states | |
| Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. | Oncologist | 2017 | united states |
|
| Progressive multifocal leukoencephalopathy and hematologic malignancies: a single cancer center retrospective review. | Blood Adv | 2017 | united states |
|
| An integrated model for detecting significant chromatin interactions from high-resolution Hi-C data. | Nat Commun | 2017 | england |
|
| Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers? | Transl Lung Cancer Res | 2017 | china |
|
| Investigation of patterns of nodal metastases in BRAF mutant lung cancer. | Lung Cancer | 2017 | ireland |
|
| Depressive symptoms predict cancer caregivers' physical health decline. | Cancer | 2017 | united states |
|
| Efficacy of meaning-centered group psychotherapy for cancer survivors: a randomized controlled trial. | Psychol Med | 2017 | england |
|
| A classifier integrating plasma biomarkers and radiological characteristics for distinguishing malignant from benign pulmonary nodules. | Int J Cancer | 2017 | united states |
|
| Validation of Clinical Tools for Vaginal and Vulvar Symptom Assessment in Cancer Patients and Survivors. | J Sex Med | 2017 | netherlands |
|
| Polycomb Responds to Low Levels of Transcription. | Cell Rep | 2017 | united states |
|
| Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. | Int J Radiat Oncol Biol Phys | 2017 | united states |
|
| Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. | Nat Genet | 2017 | united states |
|
| Total Chemical Synthesis and Folding of All-l and All-d Variants of Oncogenic KRas(G12V). | J Am Chem Soc | 2017 | united states |
|
| A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D. | Gynecol Oncol | 2017 | united states |
|
| Acceptability of a Salon-Based Intervention to Promote Colonoscopy Screening Among African American Women. | Health Educ Behav | 2017 | united states |
|
| Advances in the management of conjunctival melanoma. | Surv Ophthalmol | 2017 | united states |
|
| Left-lateralization of resting state functional connectivity between the presupplementary motor area and primary language areas. | Neuroreport | 2017 | england |
|
| BCOR-CCNB3 Fusion Positive Sarcomas: A Clinicopathologic and Molecular Analysis of 36 Cases With Comparison to Morphologic Spectrum and Clinical Behavior of Other Round Cell Sarcomas. | Am J Surg Pathol | 2017 | united states | |
| Proportion of cancer in a Middle eastern country attributable to established risk factors. | BMC Cancer | 2017 | england |
|
| Packaging and transfer of mitochondrial DNA via exosomes regulate escape from dormancy in hormonal therapy-resistant breast cancer. | Proc Natl Acad Sci U S A | 2017 | united states |
|
| Will the circle be unbroken: specific mutations in the yeast Sm protein ring expose a requirement for assembly factor Brr1, a homolog of Gemin2. | RNA | 2017 | united states |
|
| Health-related quality of life results from the phase III CheckMate 067 study. | Eur J Cancer | 2017 | england |
|
| Precision oncology for acute myeloid leukemia using a knowledge bank approach. | Nat Genet | 2017 | united states |
|
| Correlation of Handheld Reflectance Confocal Microscopy With Radial Video Mosaicing for Margin Mapping of Lentigo Maligna and Lentigo Maligna Melanoma. | JAMA Dermatol | 2017 | united states |
|
| Periprostatic adipose inflammation is associated with high-grade prostate cancer. | Prostate Cancer Prostatic Dis | 2017 | england |
|
| Diagnostic dilemmas and pitfalls in ThinPrep® cytology of breast fine needle aspiration biopsy:: Report of Six Cases with Histological Correlates. | Diagn Cytopathol | 2017 | united states |
|
| Robotic nipple-sparing mastectomy for the treatment of breast cancer: Feasibility and safety study. | Breast | 2017 | netherlands |
|
| 21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer. | Breast Cancer Res Treat | 2017 | netherlands |
|
| Contrast-enhanced MDCT in patients with pancreatic neuroendocrine tumours: correlation with histological findings and diagnostic performance in differentiation between tumour grades. | Clin Radiol | 2017 | england |
|
| Organizational Strategies for Building Capacity in Evidence-Based Oncology Nursing Practice: A Case Report of an Australian Tertiary Cancer Center. | Nurs Clin North Am | 2017 | united states | |
| Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas. | Oncogene | 2017 | england |
|
| The MukB-topoisomerase IV interaction is required for proper chromosome compaction. | J Biol Chem | 2017 | united states |
|
| A Communication Training Program to Encourage Speaking-Up Behavior in Surgical Oncology. | AORN J | 2017 | united states |
|
| Checkpoint inhibition and melanoma: Considerations in treating the older adult. | J Geriatr Oncol | 2017 | netherlands |
|
| Menopause Is a Determinant of Breast Aromatase Expression and Its Associations With BMI, Inflammation, and Systemic Markers. | J Clin Endocrinol Metab | 2017 | united states |
|
| Prospective Trial Evaluating the Surgical Anastomosis at One-Year Colorectal Cancer Surveillance: CT Colonography Versus Optical Colonoscopy and Implications for Patient Care. | Dis Colon Rectum | 2017 | united states |
|
| Tanning and Teens: Is Indoor Exposure the Tip of the Iceberg? | Cancer Epidemiol Biomarkers Prev | 2017 | united states |
|
| Urothelial neoplasms in pediatric and young adult patients: A large single-center series. | J Pediatr Surg | 2017 | united states | |
| Metastatic cutaneous apocrine carcinoma: Multidisciplinary approach achieving complete response with adjuvant chemoradiation. | JAAD Case Rep | 2017 | united states |
|
| Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib. | Lung Cancer | 2017 | ireland |
|
| Dissecting Glioma Invasiveness in a 3D-Organotypic Model. | Trends Mol Med | 2017 | england |
|
| Loss of expression of SMARCA4 (BRG1), SMARCA2 (BRM) and SMARCB1 (INI1) in undifferentiated carcinoma of the endometrium is not uncommon and is not always associated with rhabdoid morphology. | Histopathology | 2017 | england | |
| Impact of Bilateral Prophylactic Mastectomy and Immediate Reconstruction on Health-Related Quality of Life in Women at High Risk for Breast Carcinoma: Results of the Mastectomy Reconstruction Outcomes Consortium Study. | Ann Surg Oncol | 2017 | united states |
|
| Project Title: | Cancer center support grant | |
| Project Number: | 5P30CA008748-47 | |
| Project web address: | Follow on NIH | |
| Title | Year |
|---|---|
| Methods of detection of cancer using peptide profiles | 2006 |
| Cloning and uses of the genetic locus bcl-6 | 1989 |
| Ma family polypeptides and anti-Ma antibodies | 1988 |
| Ganglioside-KLH conjugate vaccines plus QS-21 | 1987 |
| Ganglioside-KLH conjugate vaccines plus OS-21 | 1987 |
| Ganglioside-KLH conjugate vaccines plus QS-21 | 1987 |
| Ganglioslide-KLH conjugate vaccine plus QS-21 | 1987 |
| Purified human ceramide-activated protein kinase | 1986 |
| Ganglioside-KLH conjugate vaccine plus QS-21 | 1985 |
| Phenyl N-mustard linked to DNA-affinic molecules or water-soluble aryl rings, method and their use as cancer therapeutic agents | 1985 |
| Alkyl N-[3-(acridin-9-yl)amino-5-hydroxymethyl] phenylcarbamates | 1985 |
| Pigmentation associated, differentiation antigen of human melanoma and autologous antibody | 1985 |
| Monoclonal antibodies to human lung cancers and method | 1985 |
| Synthetic compounds which bind to H. pylori, and uses thereof | 1985 |
| Process for preparing purified interleukin-2 | 1985 |
| Method of treating cancer using combination of a bifunctional alkylating agent and DNA repair inhibitors | 1985 |
| Purified interleukin 2 | 1985 |
| Method to detect sensitivity to alpha-interferon therapy | 1985 |
| Monoclonal antibody panel for blood group a antigen | 1985 |
| Derivatives of chrysophanol as topoisomerase II inhibitors | 1985 |
| Synthesis of 8H-3A-aza-cyclopenta [A ]indenes and 5,10-dihydropyrrolo[1,2-B]isoquinolines derivatives and their use as antitumor therapeutic agents | 1985 |
| Monoclonal antibodies selective for prostate cancer | 1985 |
| Synthesis of glycoconjugates of the lewis y epitope and uses thereof | 1985 |
| Uses of interleukin-2 | 1985 |
| Cloning and uses of the genetic locus BCL-6 | 1985 |
| Derivatives of chryosphanol | 1985 |
| Therapeutic uses of the hypervariable region of monoclonal antibody M195 and constructs thereof | 1985 |
| Synthesis of glycoconjugates of the globo-H epitope and uses thereof | 1985 |
| 5-(9-acridinylamino)-toluidine compounds | 1985 |
| Ma family polypeptides and anti-Ma antibodies | 1985 |
| Synthesis of 4H-benzo[D]pyrrolo[1,2-A]thiazoles and indolizino[6,7-b]indole derivatives and their use as antitumor therapeutic agents | 1985 |
| Interleukin-2 dependent cytotoxic T-cell clones | 1985 |
| Synthesis of the breast tumor-associated antigen defined by monoclonalantibody MBRL and uses thereof | 1985 |
| Cloning and uses of the genetic locus bcl-6 | 1985 |
| Monoclonal antibodies against melanocytes | 1985 |
| Highly purified interleukin-2 and method | 1985 |
| Human monoclonal antibodies to cell surface antigens | 1985 |
| Cloning and uses of the genetic locus BCL-6 | 1985 |
| Therapeutic use of hypervariable region of monoclonal antibody M195 and constructs thereof | 1985 |
| Monoclonal antibodies to cell surface antigens of human malignant melanoma | 1985 |
| Human monoclonal antibodies to cancer cells | 1985 |
| System and process for microfluidics-based automated chemistry | 1985 |
| Monoclonal antibodies selective for prostate cancer and diagnostic immunoassay for prostate cancer | 1985 |
| Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents | 1985 |
| Antigen recognized by patients with antibody associated cerebellar degeneration, DNA encoding same and uses thereof | 1985 |
| Human monoclonal antibodies from lymphocytes of patients with malignant melanoma | 1985 |
| 6,7-dihydropyrrol[3,4-c]pyrido[2,3-d]pyrimidine derivatives | 1985 |
| Antigen recognized by patients with antibody associated paraneoplastic cerebellar degeneration, DNA encoding same and uses thereof | 1985 |
| Synthesis of the breast tumor-associated antigen defined by monoclonal antibody MBr1 and uses thereof | 1985 |
| Highly purified human interleukin 2 and method | 1985 |
| Synthesis of glycoconjugates of the lewis Y epitope and uses thereof | 1985 |
| 3-(9-acridinylamino)-5-hydroxymethylaniline derivatives as anticancer agents | 1985 |
| Hydroxamic acid compounds and methods of use thereof | 1985 |
| Methods for detecting minimum residual disease | 1985 |
| Synthesis of thiohydantoins | 1985 |
| Synthesis of thiohydantoins | 1985 |
| Synthesis of thiohydantoins | 1985 |
| Project Title: | Cancer center support grant | |
| Project Number: | 5P30CA008748-47 | |
| Project web address: | Follow on NIH | |
| Title | Phase | Year |
|---|---|---|
| Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | Phase 2 | 2014 |
| Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer | Phase 2 | 2014 |
| Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors | Phase 2 | 2003 |
| Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic | Phase 1 | 1995 |
| Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer | Phase 1/Phase 2 | 1995 |
| Combination Chemotherapy in Treating Patients With Advanced Solid Tumors | Phase 1 | 1995 |
| Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | Phase 1/Phase 2 | 1995 |
| Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery | Phase 1 | 1995 |
| Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | Phase 1 | 1995 |
| Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma | Phase 1/Phase 2 | 1995 |
| Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | Phase 1/Phase 2 | 1995 |
| Dabrafenib and Lapatinib Ditosylate in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery | Phase 1 | 1995 |
| Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer | Phase 3 | 1985 |
| Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye | Phase 2 | 1985 |
| Nivolumab in Treating Patients With High-Risk Non-Metastatic Kidney Cancer | Phase 1 | 1985 |
| High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors | Phase 2 | 1985 |
| Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate Cancer | Phase 1 | 1985 |
| Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer | Phase 3 | 1985 |
| Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer | N/A | 1985 |
| Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia | Phase 2 | 1985 |
| Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors | Phase 1 | 1985 |
| Depression Screening in Patients With Lung Cancer | N/A | 1985 |
| Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma | Phase 2 | 1985 |
| MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma | Phase 2 | 1985 |
| Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies | Phase 1/Phase 2 | 1985 |
| Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma | Phase 2 | 1985 |
| Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer | N/A | 1985 |
| Development of a Questionnaire to Evaluate Patient Expectations for Breast Reconstruction in Women With Breast Cancer or Other Conditions | N/A | 1985 |
| Factors Affecting Decisions About Breast Reconstruction After Mastectomy in Black and Latina Women | N/A | 1985 |
| Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | Phase 2 | 1985 |
| Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer | Phase 1 | 1985 |
| Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer | Phase 2 | 1985 |
| Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy | Phase 2 | 1985 |
| T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia | Phase 2 | 1985 |
| PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery | Phase 2/Phase 3 | 1985 |
| CT Scans in Guiding the Treatment of Patients With Prostate Cancer Who Are Undergoing Radiation Therapy | Phase 2 | 1985 |
| Sho-Saiko-To Following Removal of Liver Cancer By Embolization in Treating Patients With Liver Cancer That Cannot Be Surgically Removed | Phase 2 | 1985 |
| Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast Cancer | Phase 1 | 1985 |
| Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin | Phase 2 | 1985 |
| Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment | Phase 1/Phase 2 | 1985 |
| Irinotecan, Radiation Therapy, and Docetaxel With or Without Cisplatin in Treating Patients With Locally Advanced Esophageal Cancer | Phase 1 | 1985 |
| Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic Leukemia | Phase 1 | 1985 |
| Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma | Phase 2 | 1985 |
| Positron Emission Tomography Before Surgery in Evaluating Women With Primary or Recurrent Breast Cancer | Phase 1 | 1985 |
| Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas | Phase 2 | 1985 |
| Risk Factors for Endometrial Cancer in Black Women | N/A | 1985 |
| Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission | Phase 2 | 1985 |
| Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia | Phase 2 | 1985 |
| Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors | Phase 1 | 1985 |
| Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma | Phase 1 | 1985 |
| Multiple Therapies in Treating Patients With Advanced Neuroblastoma | Phase 2 | 1985 |
| Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer | N/A | 1985 |
| Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma | Phase 2 | 1985 |
| Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib | Phase 2 | 1985 |
| Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer | Phase 2 | 1985 |
| Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas | Phase 2 | 1985 |
| Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer | Phase 1 | 1985 |
| Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma | Phase 1 | 1985 |
| GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma | Phase 2 | 1985 |
| Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer | Phase 2 | 1985 |
| Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia, Osteosarcoma, or Non-Hodgkin's Lymphoma | Phase 2 | 1985 |
| Combination Chemotherapy in Treating Patients With Bladder Cancer | Phase 3 | 1985 |
| Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation | Phase 1 | 1985 |
| Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer | Phase 2 | 1985 |
| Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma | Phase 1/Phase 2 | 1985 |
| Bortezomib in Treating Patients With Lymphoproliferative Disorders | Phase 2 | 1985 |
| Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma | Phase 3 | 1985 |
| Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma | Phase 2 | 1985 |
| Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer | Phase 2 | 1985 |
| Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer | Phase 1 | 1985 |
| Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer | Phase 2 | 1985 |
| Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma | Phase 1/Phase 2 | 1985 |
| RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma | Phase 1 | 1985 |
| IMC-A12 in Treating Patients With Advanced Liver Cancer | Phase 2 | 1985 |
| Anal Sphincter Prosthesis in Treating Patients Who Are Undergoing Surgery for Anal or Rectal Cancer | N/A | 1985 |
| Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction | Phase 2 | 1985 |
| Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment | Phase 2 | 1985 |
| Ethanol-Lock Treatment in Preventing Central Venous Catheter Infections in Patients With High-Risk Neuroblastoma | Phase 1 | 1985 |
| Couples Therapy to Enhance Intimacy Between Patients With Advanced or Recurrent Prostate Cancer and Their Partners | N/A | 1985 |
| Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia | Phase 2 | 1985 |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors | Phase 1/Phase 2 | 1985 |
| Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer | Phase 1 | 1985 |
| Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer | Phase 2 | 1985 |
| Testosterone in Treating Patients With Progressive Prostate Cancer That No Longer Responds to Hormone Therapy | Phase 1 | 1985 |
| PET Scan in Treating Patients With Metastatic Prostate Cancer | N/A | 1985 |
| Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors | Phase 2 | 1985 |
| Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma | Phase 2 | 1985 |
| Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma | Phase 2 | 1985 |
| Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma | Phase 2 | 1985 |
| Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer | Phase 2 | 1985 |
| Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer | Phase 2 | 1985 |
| Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma | Phase 1 | 1985 |
| Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma | Phase 2 | 1985 |
| Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma | Phase 2 | 1985 |
| Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Phase 1 | 1985 |
| Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma | Phase 1 | 1985 |
| Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer | Phase 2 | 1985 |
| Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer | Phase 1 | 1985 |
